VEGFA and Sepsis: In mouse CLP-sepsis, treatment with anti-VEGF neutralising antibody bevacizumab at 0.1 mg/kg i.p. 1 h before CLP or 6 h after CLP improved survival rate (173), though these findings could not be reproduced in a later study in which bevacizumab was administered at 0.5 mg/kg i.p. immediately prior to CLP (174).